RxDoctor Payments Data

Kim Runser

Family · van Wert, OHNPI 1770003964

Payments from drug & device makers

$3,124in general payments, 2019–2025

Across 193 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$905
  • AstraZeneca$469
  • Novo Nordisk$331
  • Lilly USA, LLC$220
  • Otsuka America Pharmaceutical, Inc.$199
  • Amgen$139
  • plus $861 from 21 others

What the payments were for

  • Food & beverage$3,10499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,124 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$127,731
JardianceEmpagliflozin39$45,985
RybelsusSemaglutide33$41,938
EliquisApixaban37$34,832
FarxigaDapagliflozin Propanediol28$33,333
MounjaroTirzepatide32$32,829
JanuviaSitagliptin Phosphate20$28,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,270
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$19,882
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,599
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$15,535
EntrestoSacubitril/Valsartan13$11,964
Tresiba Flextouch U-200Insulin Degludec11$6,693
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,830
Pantoprazole Sodium179$2,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$331$169,669119 claims
Boehringer IngelheimJardiance$51$45,98539 claims
AstraZenecaFarxiga, Symbicort$469$35,65339 claims
PfizerEliquis$71$34,83237 claims
Lilly USA, LLCMounjaro$220$32,82932 claims
GSKTrelegy Ellipta$53$25,27028 claims
NovartisEntresto$13$11,96413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in van Wert

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →